SUPPLEMENTARY DATA

Investigators in the Study of Osteoporotic Fractures Research Group: San Francisco Coordinating Center (California Pacific Medical Center Research Institute and University of California San Francisco): SR Cummings (principal investigator), DC Bauer (co-investigator), DM Black (co-investigator), W Browner (co-investigator) , PM Cawthon (co-investigator), N Lane (co-investigator), MC Nevitt (co-investigator), C McCulloch (co-investigator), A Schwartz (co-investigator), KL Stone (co-investigator), G Tranah (co-investigator), K Yaffe (co-investigator) , R Benard, T Blackwell, L Concepcion, D Evans, S Ewing, C Fox, R Fullman, SL Harrison, M Jaime-Chavez, D Kriesel , W Liu, L Lui, L Palermo, N Parimi, K Peters, M Rahorst, C Schambach, J Ziarno.

University of Maryland: MC Hochberg (principal investigator), R Nichols (clinic coordinator), S Link.

University of Minnesota: KE Ensrud (principal investigator), S Diem (co-investigator), M Homan (co-investigator), P Van Coevering (program coordinator), S Fillhouer (clinic director), N Nelson (clinic coordinator), K Moen (assistant program coordinator), K Jacobson, M Forseth, R Andrews, S Luthi, Atchison, L Penland-Miller.

University of Pittsburgh: JA Cauley (principal investigator), LH Kuller (co-principal investigator), JM Zmuda (co-investigator), L Harper (project director), L Buck (clinic coordinator), M Danielson (project administrator), D Cusick, A Flaugh, M Gorecki, C Newman.

The Kaiser Permanente Center for Health Research, Portland, Oregon: T Hillier (principal investigator), K Vesco (co-investigator), K Pedula (co-investigator), J Van Marter (project director), M Summer (clinic coordinator), A MacFarlane, J Rizzo, K Snider, J Wallace.

SUPPLEMENTARY DATA

Supplementary Table S1. Cardiovascular disease mortality according to diabetes and bilateral oophorectomy status and age at menopause accounting for the competing risk of other non-CVD causes, The Study of Osteoporotic Fractures

		Age Adjusted	Multivariable adjusted*
Variables	Events	HR (95%CI)	HR (95%CI)
No diabetes or BSO	1209	1 (Referent)	1 (Referent)
Diabetes; no BSO	132	1.87 (1.55-2.25)	1.94 (1.59-2.35)
BSO; no diabetes	261	1.04 (0.91-1.18)	1.02 (0.87-1.20)
Diabetes and BSO	35	2.22 (1.56-3.16)	2.52 (1.73-3.67)
P interaction		, ,	0.218
Age at menopause			
Diabetes			
NO BSO \leq 45y	44	1 (Referent)	1 (Referent)
$BSO \le 45y$	17	1.57 (0.93-2.66)	2.66 (1.25-5.68)
NO BSO $> 45y$	88	1 (Referent)	1 (Referent)
BSO > 45y	18	1.20 (0.72-1.99)	0.95 (0.49-1.83)
Non Diabetes			
NO BSO $\leq 45y$	389	1 (Referent)	1 (Referent)
$BSO \le 45y$	102	1.12 (0.90-1.39)	1.05 (0.81-1.35)
NO BSO $> 45y$	820	1 (Referent)	1 (Referent)
BSO > 45y	159	1.10 (0.93-1.30)	0.96 (0.77-1.20)

^{*} Adjusted for age, education, age at menopause, hysterectomy, parity, postmenopausal hormone use, BMI, waist hip ratio, hypertension, smoking status and physical activity. BSO: bilateral oophorectomy